Formats
  1. Journal Article (66881)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3755)
  5. Editorial (2168)
  6. Conference Paper (1526)
  7. Correspondence (665)
  8. Guidelines (662)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39053)
  2. GSK Faculty (22471)
  3. Solid Tumor Oncology Division (22069)
  4. Surgery (21267)
  5. Survivorship Research (15771)
  6. Sloan Kettering Institute Faculty (15654)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1051)

More People

Years
  1. 2025 (2138)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7193)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115606)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy and safety of tabelecleucel in patients with Epstein-Barr virus-positive (EBV(+)) leiomyosarcomas (LMS)
    Meeting Abstract

    Jimenez-Kurlander, L. S.; Behr, G.; Bunin, N. J.; Doubrovina, E.; Dinavahi, R.; Gamelin, L.; Ghobadi, A.; Mascarenhas, L.; Nikiforow, S.; O'Reilly, R. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Antigen directed therapy pre-transplant confers superior post-transplant survival outcome compared to conventional chemotherapy in pediatric patients with relapsed and refractory B-ALL
    Meeting Abstract

    Stiefel, J.; Flower, A. M.; Botwinick, M.; Ford, M.; Foti, A.; Gandhi, M.; Slovin, J.; Smilow, E.; Bowers, A.; Karpel, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups
    Meeting Abstract

    Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Meeting Abstract

    Nooka, A. K.; Cohen, A.; Lee, H. C.; Badros, A. Z.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S.; Brown, J. R.; Mato, A. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The mutagenic impact of radiotherapy in multiple myeloma
    Meeting Abstract

    Diamond, B.; Poos, A. M.; Ziccheddu, B.; Maclachlan, K. H.; Zhang, Y.; Usmani, S.; Boyle, E. M.; Davies, F. E.; Morgan, G. J.; Landgren, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience
    Meeting Abstract

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mohan, S. R.; Chase, C. C.; Berdeja, J. G.; Karlin, L.; Belhadj, K.; Perrot, A.; Moreau, P.; Touzeau, C.; Chalopin, T.; Lesokhin, A. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Patterns of childbirth in women with myeloproliferative neoplasms
    Meeting Abstract

    Landtblom, A. R.; Andersson, T. M. L.; Johansson, A. L. V.; Lundberg, F. E.; Samuelsson, J.; Björkholm, M.; Hultcrantz, M.
    Blood (2022)

    Fulltext@MSK | Save